Fosun Pharma

Hong Kong – October 13, 2026 -- Fosun International (HKEX: 00656) won five awards at The Asset Corporate Sustainability Leadership Awards 2026, moving up from Gold to the Platinum Award in the main category.

The Hong Kong-listed group also took four single-category prizes: Best in Disclosure & Transition, Best Initiative in Environmental Responsibility, Best Initiative in Social Responsibility and Best Sustainability Team. The Asset is an Asia-Pacific financial publication.

Fosun's MSCI ESG rating reaches AAA and its Hang Seng rating rises to AA+

Fosun's MSCI ESG Rating now stands at the highest tier, AAA. Its Hang Seng Sustainability Rating moved from AA- to AA+, and it joined the Hang Seng ESG 50 Index. It has been a constituent of the Hang Seng Corporate Sustainability Benchmark Index for seven consecutive years.

Hong Kong – October 08, 2026 -- Sisram Medical Ltd (1696.HK) has announced a share repurchase plan to buy back up to 1% of its total issued shares on the open market, citing confidence in its long-term growth trajectory.

Buyback plan allows cancellation or treasury retention of shares

Under the existing share repurchase mandate, repurchased shares may either be cancelled or held as treasury shares depending on future capital management needs. The plan will be executed subject to market conditions, with the Board stating it will balance business development priorities, strategic investment needs and financial flexibility.

First-half 2026 revenue climbs 3.6% to US$171.4 million

Sisram reported H1 2026 revenue of US$171.4 million, up 3.6% year-on-year. International markets excluding North America drove growth, rising 16.7% YoY to US$127.0 million, with APAC generating US$78.4 million, a 19.1% YoY increase.

Hod Hasharon, Israel & Shanghai – September 07, 2026 -- Raziel Therapeutics and Fosun Pharma reported that RZL-012, an injectable lipolytic drug for submental fat reduction, met every primary and secondary endpoint in a 480-patient Phase 3 trial in China, with the primary responder rate outperforming placebo by 30 percentage points after a single treatment cycle.

Pivotal China trial clears statistical bar with wide margin over placebo

The registration study, conducted with Fosun Pharma affiliate JuveStar, enrolled 360 patients on active treatment and 120 on placebo, evaluating efficacy 84 days after one treatment cycle. Results showed a decisive statistical advantage across all measured endpoints, according to the companies.

HONG KONG -- September 01, 2026 -- Fosun International reported a 160.3% year-on-year surge in first-half profit attributable to owners of the parent to RMB1.72 billion, the conglomerate said at an interim results presentation held in Hong Kong on Aug. 28. Total revenue for the six-month period reached RMB86.96 billion, with overseas markets contributing RMB49.16 billion, or 56.5% of the total. The briefing marked Fosun's first in-person results presentation in Hong Kong in six years, attended by Chairman Guo Guangchang, Co-Chairman Wang Qunbin, Co-CEOs Chen Qiyu and Xu Xiaoliang, and CFO Gong Ping.

Four Core Units Generate 73.5% of Group Revenue

Fosun Pharma, Yuyuan, Portuguese insurer Fidelidade, and the group's tourism segment together accounted for 73.5% of total revenue in the first half, the company disclosed. Pharmaceutical and insurance operations delivered the strongest performance among the four units.